View Item 

Show simple item record

The thrombomodulin analog Solulin promotes reperfusion and reduces infarct volume in a thrombotic stroke model
dc.contributor.authorSu, E. J.en_US
dc.contributor.authorGeyer, M.en_US
dc.contributor.authorWahl, M.en_US
dc.contributor.authorMann, K.en_US
dc.contributor.authorGinsburg, David W.en_US
dc.contributor.authorBrohmann, H.en_US
dc.contributor.authorPetersen, K. U.en_US
dc.contributor.authorLawrence, D. A.en_US
dc.date.accessioned2011-11-10T15:33:11Z
dc.date.available2012-07-12T17:42:24Zen_US
dc.date.issued2011-06en_US
dc.identifier.citationSu, E. J. ; Geyer, M. ; Wahl, M. ; Mann, K. ; Ginsburg, D. ; Brohmann, H. ; Petersen, K. U. ; Lawrence, D. A. (2011). "The thrombomodulin analog Solulin promotes reperfusion and reduces infarct volume in a thrombotic stroke model." Journal of Thrombosis and Haemostasis 9(6). <http://hdl.handle.net/2027.42/86888>en_US
dc.identifier.issn1538-7933en_US
dc.identifier.issn1538-7836en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/86888
dc.publisherBlackwell Publishing Ltden_US
dc.publisherWiley Periodicals, Inc.en_US
dc.subject.otherAnticoagulantsen_US
dc.subject.otherCerebral‐Ischemiaen_US
dc.subject.otherHemorrhageen_US
dc.subject.otherStrokeen_US
dc.subject.otherThrombosisen_US
dc.titleThe thrombomodulin analog Solulin promotes reperfusion and reduces infarct volume in a thrombotic stroke modelen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelInternal Medicine and Specialtiesen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumHoward Hughes Medical Institute, University of Michigan Medical School, Ann Arbor, MI, USAen_US
dc.contributor.affiliationotherDepartment of Internal Medicineen_US
dc.contributor.affiliationotherPAION Deutschland GmbH, Aachen, Germanyen_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/86888/1/j.1538-7836.2011.04269.x.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/86888/2/JTH_4269_sm_Data-S1.pdf
dc.identifier.doi10.1111/j.1538-7836.2011.04269.xen_US
dc.identifier.sourceJournal of Thrombosis and Haemostasisen_US
dc.identifier.citedreferenceLloyd‐Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De Simone G, Ferguson TB, Ford E, Furie K, Gillespie C, Go A, Greenlund K, Haase N, Hailpern S, Ho PM, Howard V, Kissela B, Kittner S, Lackland D, Lisabeth L et al. Heart disease and stroke statistics – 2010 update: a report from the American Heart Association. Circulation 2010; 121: e46 – 215.en_US
dc.identifier.citedreferenceGreen AR. Pharmacological approaches to acute ischaemic stroke: reperfusion certainly, neuroprotection possibly. Br J Pharmacol 2008; 153: S325 – 38.en_US
dc.identifier.citedreferenceSandercock PA, Counsell C, Gubitz GJ, Tseng MC. Antiplatelet therapy for acute ischaemic stroke. Cochrane Database Syst Rev 2008; ( 3 ): CD000029.en_US
dc.identifier.citedreferenceAdams HP. Emergent use of anticoagulation for treatment of patients with ischemic stroke. Stroke 2002; 33: 856 – 61.en_US
dc.identifier.citedreferenceCamerlingo M, Salvi P, Belloni G, Gamba T, Cesana BM, Mamoli A. Intravenous heparin started within the first 3 hours after onset of symptoms as a treatment for acute nonlacunar hemispheric cerebral infarctions. Stroke 2005; 36: 2415 – 20.en_US
dc.identifier.citedreferenceSandercock P, Counsell C, Kamal AK. Anticoagulants for acute ischemic stroke. Stroke 2009; 40: e483 – 4.en_US
dc.identifier.citedreferenceEsmon CT, Owen WG. Identification of an endothelial cell cofactor for thrombin‐ catalyzed activation of protein C. Proc Natl Acad Sci U S A 1981; 78: 2249 – 52.en_US
dc.identifier.citedreferenceDahlbäck B. Physiological anticoagulation. Resistance to activated protein C and venous thromboembolism. J Clin Invest 1994; 94: 923 – 7.en_US
dc.identifier.citedreferenceLane DA, Philippou H, Huntington JA. Directing thrombin. Blood 2005; 106: 2605 – 12.en_US
dc.identifier.citedreferenceBajzar L, Morser J, Nesheim M. TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin‐thrombomodulin complex. J Biol Chem 1996; 271: 16603 – 8.en_US
dc.identifier.citedreferenceWang W, Nagashima M, Schneider M, Morser J, Nesheim M. Elements of the primary structure of thrombomodulin required for efficient thrombin‐activable fibrinolysis inhibitor activation. J Biol Chem 2000; 275: 22942 – 7.en_US
dc.identifier.citedreferenceMomi S, Leone M, Semeraro N, Morser J, Gresele P, Colucci M. Recombinant soluble thrombomodulin prevents thrombin‐induced thromboembolism in mice independently of direct thrombin inhibition. Haematologica 2000; 85: 87 – 8.en_US
dc.identifier.citedreferenceMohri M. ART‐123: recombinant human soluble thrombomodulin. Cardiovasc Drug Rev 2000; 18: 312 – 25.en_US
dc.identifier.citedreferenceCui J, Eitzman DT, Westrick RJ, Christie PD, Xu ZJ, Yang AY, Purkayastha AA, Yang TL, Metz AL, Gallagher KP, Tyson JA, Rosenberg RD, Ginsburg D. Spontaneous thrombosis in mice carrying the factor V Leiden mutation. Blood 2000; 96: 4222 – 6.en_US
dc.identifier.citedreferenceSu EJ, Fredriksson L, Geyer M, Folestad E, Cale J, Andrae J, Gao Y, Pietras K, Mann K, Yepes M, Strickland DK, Betsholtz C, Eriksson U, Lawrence DA. Activation of PDGF‐CC by tissue plasminogen activator impairs blood–brain barrier integrity during ischemic stroke. Nat Med 2008; 14: 731 – 7.en_US
dc.identifier.citedreferenceChoudhri TF, Hoh BL, Prestigiacomo CJ, Huang J, Kim LJ, Schmidt AM, Kisiel W, Connolly ES Jr, Pinsky DJ. Targeted inhibition of intrinsic coagulation limits cerebral injury in stroke without increasing intracerebral hemorrhage. J Exp Med 1999; 190: 91 – 9.en_US
dc.identifier.citedreferenceYepes M, Sandkvist M, Wong MK, Coleman TA, Smith E, Cohan SL, Lawrence DA. Neuroserpin reduces cerebral infarct volume and protects neurons from ischemia‐induced apoptosis. Blood 2000; 96: 569 – 76.en_US
dc.identifier.citedreferenceZhao BQ, Ikeda Y, Ihara H, Urano T, Fan W, Mikawa S, Suzuki Y, Kondo K, Sato K, Nagai N, Umemura K. Essential role of endogenous tissue plasminogen activator through matrix metalloproteinase 9 induction and expression on heparin‐produced cerebral hemorrhage after cerebral ischemia in mice. Blood 2004; 103: 2610 – 6.en_US
dc.identifier.citedreferenceWong KS, Chen C, Ng PW, Tsoi TH, Li HL, Fong WC, Yeung J, Wong CK, Yip KK, Gao H, Wong HB. Low‐molecular‐weight heparin compared with aspirin for the treatment of acute ischaemic stroke in Asian patients with large artery occlusive disease: a randomised study. Lancet Neurol 2007; 6: 407 – 13.en_US
dc.identifier.citedreferencePaciaroni M, Agnelli G, Micheli S, Caso V. Efficacy and safety of anticoagulant treatment in acute cardioembolic stroke: a meta‐analysis of randomized controlled trials. Stroke 2007; 38: 423 – 30.en_US
dc.identifier.citedreferenceStoll G, Kleinschnitz C, Nieswandt B. Molecular mechanisms of thrombus formation in ischemic stroke: novel insights and targets for treatment. Blood 2008; 112: 3555 – 62.en_US
dc.identifier.citedreferenceAdams HP Jr, Effron MB, Torner J, Davalos A, Frayne J, Teal P, Leclerc J, Oemar B, Padgett L, Barnathan ES, Hacke W. Emergency administration of abciximab for treatment of patients with acute ischemic stroke: results of an international phase III trial: Abciximab in Emergency Treatment of Stroke Trial (AbESTT‐II). Stroke 2008; 39: 87 – 99.en_US
dc.identifier.citedreferenceBajzar L, Nesheim ME, Tracy PB. The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI‐dependent. Blood 1996; 88: 2093 – 100.en_US
dc.identifier.citedreferenceMosnier LO, Meijers JC, Bouma BN. Regulation of fibrinolysis in plasma by TAFI and protein C is dependent on the concentration of thrombomodulin. Thromb Haemost 2001; 85: 5 – 11.en_US
dc.identifier.citedreferenceBajzar L, Kalafatis M, Simioni P, Tracy PB. An antifibrinolytic mechanism describing the prothrombotic effect associated with factor VLeiden. J Biol Chem 1996; 271: 22949 – 52.en_US
dc.identifier.citedreferenceParker AC, Mundada LV, Schmaier AH, Fay WP. Factor VLeiden inhibits fibrinolysis in vivo. Circulation 2004; 110: 3594 – 8.en_US
dc.identifier.citedreferenceXi G, Reiser G, Keep RF. The role of thrombin and thrombin receptors in ischemic, hemorrhagic and traumatic brain injury: deleterious or protective? J Neurochem 2003; 84: 3 – 9.en_US
dc.identifier.citedreferenceHua Y, Keep RF, Hoff JT, Xi G. Brain injury after intracerebral hemorrhage: the role of thrombin and iron. Stroke 2007; 38: 759 – 62.en_US
dc.identifier.citedreferenceXue M, Hollenberg MD, Yong VW. Combination of thrombin and matrix metalloproteinase‐9 exacerbates neurotoxicity in cell culture and intracerebral hemorrhage in mice. J Neurosci 2006; 26: 10281 – 91.en_US
dc.identifier.citedreferenceGuo H, Singh I, Wang Y, Deane R, Barrett T, Fernandez JA, Chow N, Griffin JH, Zlokovic BV. Neuroprotective activities of activated protein C mutant with reduced anticoagulant activity. Eur J Neurosci 2009; 29: 1119 – 30.en_US
dc.identifier.citedreferenceWang Y, Thiyagarajan M, Chow N, Singh I, Guo H, Davis TP, Zlokovic BV. Differential neuroprotection and risk for bleeding from activated protein C with varying degrees of anticoagulant activity. Stroke 2009; 40: 1864 – 9.en_US
dc.identifier.citedreferenceHemker HC, Al Dieri R, De Smedt E, Beguin S. Thrombin generation, a function test of the haemostatic‐thrombotic system. Thromb Haemost 2006; 96: 553 – 61.en_US
dc.identifier.citedreferenceFumagalli R, Mignini MA. The safety profile of drotrecogin alfa (activated). Crit Care 2007; 11 ( Suppl. 5 ): S6.en_US
dc.identifier.citedreferencevan Iersel T, Stroissnig H, Giesen P, Wemer J, Wilhelm‐Ogunbiyi K. Phase I study of Solulin, a novel recombinant soluble human thrombomodulin analogue. Thromb Haemost 2010; 105: 302 – 12.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
j.1538-7836.2011.04269.x.pdf
Size:
440.9KB
Format:
PDF
View/Open
Name:
JTH_4269_sm_Data-S1.pdf
Size:
33.89KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.